• How a college biology class lead to a Genentech internship
• Getting inspired to pursue her PhD 
• Working with influential scientists at DNAX
• Joining an investment club and pursuing the intersection of science and business
• Transitioning out of DNAX and cold calling people for her next opportunity

• Ecotone AI's mission: leveraging AI to decode the human genome and address rare genetic diseases.
• Ecotone's approach: using diffusion transformers to model genomes and generate synthetic genomic data.
• eMalick’s focus on intentional company building to ensure sustainable growth.
• Ecotone’s upcoming advancements in AI and genetics.

• Founding Genetic Intelligence and its mission to combine AI and genetics
• Challenges of founding a company, personal sacrifices, and breakthroughs leading to NSF recognition
• How company culture and leadership shifts led eMalick to leave Genetic Intelligence
• The importance of building teams aligned with the original vision
• Discovering population genetics through AI and the birth of Ecotone

• Answering the question “What is memory?”
• How playing “Stump the Professor” led eMalick to Columbia
• Studying C Eligans in a sandals-wearing lab
• The wide applicable uses for AI and ML in research
• Wanting to help people at scale

• Growing up with hippie parents in the Gambia
• Being in the first neuroscience class in the country at Northeastern University
• Lessons learned in one on one conversations with a CEO
• Experience working with Dr. Alice Ting while at MIT
• Sticking to his principles and leaving MIT

• Barbara’s unexpected pivot into banking
• Her transition from SVB to J.P. Morgan
• Her unique life sciences and entrepreneurial backgrounds
• The importance of mentorship, resilience, and seizing unexpected opportunities
• Navigating the challenges of building a career in both science and finance

• Barbara’s transition from academia to entrepreneurship and industry 
• Her experience co-founding Biochron, which built technologies to track biological aging using AI/ML
• The challenges of early-stage company building
• Her time as a mentor at the Manos Accelerator, and investment experience in early-stage ventures as a Senior Fellow at Life Science Angels
• Advice for improving your investor pitch and connecting with the right people

• Barbara’s academic journey and graduate school lab experience at UC Irvine
• Her insights from her time at the Beckman Laser Institute and her groundbreaking research on DNA repair using lasers
• Her international fellowship at King's College London, where she explored stem cell biology
• How her transition to entrepreneurship was shaped by navigating different lab environments and overcoming funding challenges

• Barbara’s immigrant journey and how her upbringing played an important role in her lead-up to becoming a scientist-entrepreneur. 
• Her path from community college to UC Irvine, where she gained essential lab experience, secured a research position in Plant Biology.
• Her travels abroad to the National Autonomous University of Mexico.

• The process of building and scaling Xcelience, from leveraging innovative technology to disrupt the market to navigating the impact of the 2008 Recession
• Derek’s experience with strategic buy-side and sell-side transactions 
• His commitment to continuous learning
• His transition into investing and work as a board member

• Derek’s transition from commercial roles to Operations, managing a challenging site in Egypt, and the teamwork that turned it around
• His move to a Biologics site in Montreal and the hurdles he faced there overseeing GMP Operations
• The start of his entrepreneurial journey: buying a portion of a business and founding Xcelience.

• Derek’s early challenges and financial hurdles he faced after moving to Europe for his MBA
• His first role in business development
• His managing transition, learning the ropes of leadership, and his joint venture experience in Mexico
• Derek’s intricacies of managing a matrix organization and his experience as a product manager

• Derek’s childhood and his early interest in history and science
• His academic journey in microbiology at the University of Alberta, where he shifted from chemistry to biology, and his eventual move into sales.
• His MBA experience in the Netherlands and his current outlook on the degree.

• Doug’s first-time experience running a public company: the challenges of hitting quarterly numbers and juggling the pressure of share price volatility
• His move to Cybin, a startup transforming psychiatric treatments through psychedelic compounds
• Cybin’s recent progress, including some key acquisitions, taking the company public, and their breakthrough therapies in depression and anxiety.

• Doug’s transition from BD to leading M&A at Actavis
• His insights on leveraging debt for acquisitions
• The importance of cultural fit in successful deals
• Doug’s strategic acquisitions at Actavis and the turnaround at Norwich Pharmaceuticals & Alvogen
• His challenges and successes at Pernix Therapeutics, the first public company Doug worked for

• Doug’s experience in business development
• His move from crunching numbers to leading deals
• The challenges of global BD strategies
• Doug’s move from the UK to San Diego
• His intricacies of licensing and acquisitions in the pharma industry, and his experiences with Elan, Alpharma, and Actavis 

• Doug’s upbringing in a working-class setting
• His life-changing scholarship and his early passion for the life sciences
• Doug’s pivotal moments in the lab and his transition to sales at DuPont Merck
• His time at Elan, where he combined his scientific and commercial expertise to excel in BD

• Noam's unique dynamics of working with academic institutions and the alignment of incentives that come with collaborating with top researchers
• The importance of strategic partnerships and the meticulous analysis involved in selecting the right collaborators
• Noam’s fundraising journey
• The technological advancements at Immunai
• The application of AI in optimizing drug development processes

• How the human genome project gave us the alphabet to read the book that is the human immune system
• Immunai’s philosophy of doing what's right even if they don’t know what they’re doing
• Balancing a CEO’s naivete with being selective about who’s advise to take
• What single cell multi-omics, the technology behind Immunai, really means
• Why working with different pharma companies is like dancing with a gorilla
  
  

• The impact of attending prestigious institutions like Harvard and MIT on his career and networking opportunities
• The genesis of Immunai, inspired by personal experiences and focused on precision medicine in cancer treatment
• Explaining AI and Machine Learning, their distinctions, and the current state of AI in biology and drug development
• The complexity of the immune system and Immunai's ambitious goal to map it completely
• The convergence of technological advancements (single-cell technology, computing power, and AI models) that created the "perfect storm" for founding Immunai
  
  

• Noam's early years and how his upbringing shaped his high standards and competitive spirit which led him to excel in the world of academia
• His unique experience of starting university at the age of 14
• His early love for mathematics
• His pursuit of multiple PhDs in math and computer science
• The importance of resilience, critical thinking, and creativity needed as an entrepreneur

• Shekhar’s experience at Procter & Gamble and the intrapreneurial opportunities he found there, sharing how these experiences laid the foundation for his future endeavors as an entrepreneur and mentor.
• His involvement in developing an innovative drug from natural sources.
• His involvement in new ventures, from a company creating an innovative mouth piece to a plant extract rejuvenating mitochondria
• His work with the Cincinnati Art Museum and the Society of Asian Scientists and Engineers, highlighting his commitment to community, diversity, creativity, and leadership in both the arts and STEM fields.

• 
  The challenges of building the first big innovation center in Asia
• Giving people a chance to impress you and what the whole work of leadership is
• Building emotional bonds and noticeability in your customer base 
• The importance and impact of developing emotional drivers in your customers 
• And much more!

• Shekar’s time at Columbia and Yale collaborating with top-notch physicists, and his involvement in the Jane Coffin Fellowship
• His move from Academia and laser light studies to Procter & Gamble
• Navigating the challenges, failures, and successes along the way
• His experience leading key clinical investigations and working with the FDA

• Shekhar’s upbringing in a multigenerational household and the values that instilled in him
• His journey through graduate school
• The groundbreaking research he conducted investigating complex biological systems
• His diverse experiences in New York City from intense lab work to exploring the city’s vibrant cultural scene
• And much more!

• Nathan’s experience with data integration and automation in the life sciences and building a product for bioinformatics engineers and data scientists 
• His experience building the technical team and creating a go-to-market motion
• His vision for Ganymede in the years to come
• The challenges biotech companies face managing and analyzing large amounts of data 
• The importance of streamlining processes through automation and data integration

• Parallels between Benchling and Salesforce
• How solving problems his customers didn’t even know were there encouraged them to fully adopt his products
• The importance of managing the writhing snake of data for scientists
• Ganymede’s journey to achieving escape velocity type growth
• And much more!

• Nathan’s move from Goldman Sachs to a Product Management role at Affirm
• His experience managing several data products at Benchling
• The importance of understanding user needs, aligning product development with real-world problems, and accelerating scientific progress by addressing the challenges researchers face today.

• Nathan’s childhood and the influence of his entrepreneurial father
• His experience studying business and finance at the University of North Carolina at Chapel Hill
• His role at Goldman Sachs and the importance of liquidity, risk management, and attention to detail in the fast-paced trading environment
• Transferable skills and lessons that can benefit entrepreneurs in any industry
• And much more!

• David’s transition from private equity to co-founding Meliora and using AI/ML in drug development
• His fundraising experiences for Meliora and current outlook on the fundraising landscape in 2024 
• His advice for aspiring entrepreneurs and reflections on “thinking big” in biotech
• Identifying mischaracterized mechanisms of action and establishing Meliora as a drug development company and computational platform

• Working at Everest Detection and developing a blood-based lung cancer test
• Excelling in a non-iterative work environment
• How software and biotech companies think about product market fit differently
• Why money is a super power for biotech startups today
• And much more!

• David’s pivot from finance roles at Goldman Sachs and KKR to early-stage entrepreneurship in the Life Sciences
• The challenges of moving from private equity to startups
• Aligning personal values with career choices, building solid teams, and the role of luck in success.
• His time at Benchling as Head of Commercial Operations and at Everest Detection as the Chief Business Officer

• David's childhood in China and Kentucky 
• Developing a passion for biology and chemistry at a young age
• His experience in the University of Pennsylvania Life Sciences Management Program
• His experience at Goldman Sachs, insights he's gained from Fortune 500 CEOs, his mentorship through Need You in New York City
• His ongoing commitment to innovation and patient impact
• And much more!

Long-Form Video Timestamps:

• The evolution of bit.bio and their mission to democratize access to human cells and therapies
• Building a solid infrastructure and hiring the right people
• The early hurdles of securing funding and managing co-founder dynamics and bit.bio’s financial journey from angel investments to institutional funding 
• Mark’s plans to take the company public

• Gene expression discoveries and the technology bit.bio is developing around them
• Vital questions and concepts that every founder should know before they start developing their company
• The benefits of founder-led companies and their relentless focus on their mission
• And much more!

• Transition from his PhD studies at Cambridge to the Medical University of Vienna, where he became a resident in neurosurgery and ran his own research group
• Experience at the Max Planck Institute for Experimental Medicine
• Return to Cambridge, where he combined clinical practice with research
• Shift from academia to entrepreneurship, which led to the founding of his first biotech startup

• Mark's upbringing as a curious child in Canada and his exposure to a broad range of cultures and perspectives
• His experiences growing up with dyslexia and how it led him to focus on science and mathematics at an early age 
• His experience as a researcher and PhD student at Cambridge, where he transitioned from medicine to synthetic biology and stem cell research
• And much more!

• Unique journey through Y Combinator and its impact
• Thoughts about empathy’s role in organizational and team dynamics
• Strategies for adapting as an entrepreneur in a shifting biotech landscape
• Experience expanding Ochre Bio globally and the challenges of scaling
• Fundraising journey and his unconventional tips for aspiring entrepreneurs

• Working at the Mayo Clinic’s Single Cell Consortium at The University of Oxford
• The dynamics of collaboration between academia and industry, including lessons learned from his time at Novo Nordisk
• The founding principles and evolution of Ochre Bio
• Pivoting towards a bioinformatics approach